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Purpose: We examined the influence of body mass index (BMI) and body fat distribution on rectal dose in patients
treated with permanent seed brachytherapy for localized prostate cancer.
Methods and materials: We analyzed 213 patients treated with I125 seed brachytherapy for localized prostate
cancer. BMI and rectal dosimetry data for all patients were available. Data on visceral and subcutaneous fat
distribution at the level of the iliac crest (n = 140) as well as the distribution of periprostatic and subcutaneous fat at
the symphysis pubis level were obtained (n = 117). Fat distribution was manually contoured on CT on day 30 after
brachytherapy. The correlation between BMI, fat distribution and rectal dose (R100 (in cc), R150 (cc), D2 (Gy)) was
analyzed using the Spearman correlation coefficient. Differences in rectal dose between tertiles of body fat
distribution were calculated using nonparametric tests.
Results: Periprostatic adipose was only weakly correlated with BMI (r = 0.0.245, p = 0.008) and only weakly
correlated with the other fat measurements (r = 0.31-0.37, p < 0.001). On the other hand, BMI was correlated with all
other fat measurements (≥0.58, p < 0.001). All the other fat measurements were strongly correlated with each other
(r = 0.5-0.87, p < 0.001). Patients with an R100 of >1.3 cc (23% of patients) had less visceral fat (p = 0.004), less
subcutaneous fat at the level of the iliac crest (p = 0.046) and a lower BMI (26.8 kg/m2 vs. 28.5 kg/m2, p = 0.02) than
patients with an R100 of <1.3 cc. Results were very similar when comparing an R100 of >1.0 cc (34% of patients)
across the tertiles. None of the tested linear regression models were predictive (max 12%) of dose to the rectum.
Conclusion: Dose to the rectum is dependent on BMI and body fat distribution. Periprostatic fat does not influence
rectal dose. Dose to the rectum remains difficult to predict and depends on many factors, one of which is body fat
distribution.
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Several studies have shown a dose-volume dependence on
rectal bleeding after permanent seed brachytherapy (BT)
[1-4]. Consequently, several European societies have pub-
lished guidelines regarding the rectal dose [5].
Currently, little is known about the factors that might
influence the dose to the rectum in BT. Some studies have
shown that rectal dose decreases with the physician’s* Correspondence: daniel.taussky.chum@ssss.gouv.qc.ca
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unless otherwise stated.clinical experience [6] while others found no such effect.
Certain groups [7] found that the dose to the rectum in-
creased with prostate volume [8]. Recently, Patil et al.
[9] identified body mass index (BMI) as one of several
factors that are negatively correlated with rectal dosimetry.
It is clear that little consensus exists regarding which vari-
ables have an impact on the rectal dose in BT.
BMI has often been used as a surrogate for adipose tis-
sue. We hypothesized that directly measuring adipose tis-
sue distribution, especially around the prostate, would
more accurately predict the dose to the rectum than using
BMI alone.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Our cohort consisted of both low-risk patients (stage T1c-
T2a, PSA level ≤10 ng/mL and Gleason score ≤6) and
lower tier intermediate risk patients (T2b or PSA level 10-
20 ng/mL or Gleason 7 in ≤30% of biopsies) as defined by
the 2010 American Joint Committee on Cancer (AJCC)
clinical stage guidelines [10]. The patients had no history
of prior hormonal therapy and were exclusively treated
with permanent iodine-125 seed brachytherapy to 144Gy
(BT) with an intraoperative planning system.
Adipose tissue measurements were available for pa-
tients who were part of two prior studies in our center
investigating the influence of adipose tissue distribution
on PSA bounce after BT [11,12]. The BMI was calcu-
lated for all these patients. Height and weight data were
obtained from preoperative records.
Adipose tissue distribution was measured on com-
puted tomography (CT) scan images obtained 30 days
following BT.
All adipose tissue was contoured manually using the
Eclipse treatment planning system (Varian Medical Sys-
tems, Inc., Palo Alto, CA) on three consecutive 3 mm
slices. Periprostatic adipose tissue was contoured anteri-
orly and posteriorly to the prostate from the level of the
superior border of the symphysis onwards in the caudal
direction (Figure 1a). Unlike other studies that includedFigure 1 Adipose tissue measurements (a) periprostatic fat
(pink), and subcutaneous fatat symphysis pubis level (yellow).
(b) abdominal visceral fat (orange) and subcutaneous adipose tissue
at the level of the iliac crest (green).the tissue medial to the levator ani muscles in their cal-
culation of periprostatic fat [13], we chose to exclude
this area since it is dependent on rectal filling and thus
highly variable. Subcutaneous adipose tissue at the sym-
physis level was contoured from the upper level of the
pubic symphysis onwards in the caudal direction on
three 3-mm slices (Figure 1a). Visceral fat and again the
subcutaneous fat were measured from the iliac crest on-
wards in the caudal direction on three slices that often
corresponds to the 4th lumbar vertebra (Figure 1b).
Most patients with fat measurements were part of two
studies investigating the influence of fat distribution on
PSA-bounce. However, only one study (n = 54) [11] in-
cluded measurement of periprostatic fat in addition to
the other measurements. The other study (n = 68) [12]
measured most of the other fat distributions. We then
randomly added other patients from our database that
received permanent seed brachytherapy and measured
their fat distribution and the BMI. All patients with fat
measurements also had BMI data. BMI was available for
211 patients, perirpostatic fat in 116, subcutaneous fat at
the symphysis level in 113 and at the iliac crest level in
136 patients and visceral fat in 139 patients.
All patients with fat measurements also had rectal
dosimetry available. Rectal dosimetry was measured on
CT scan images obtained 30 days following brachyther-
apy. The anterior rectum wall was contoured on all
slices where prostate was visible. Dose-volume points
analyzed were the volume in cubic centimeters of the
anterior rectal wall receiving 100% and 150% of the pre-
scribed dose (R100 and R150 in cc) and the isodose that
encompassed 2% of the rectal volume (D2 in Gy). This
retrospective analysis was approved by the institutional
review board of the Centre Hospitalier de l’Université de
Montréal (CHUM), approval number 12.240
Statistical methods
The correlation between BMI, adipose tissue distribu-
tion, clinical factors and rectum dosimetry was analyzed
using the Spearman correlation coefficient.
Differences in rectal dose between tertiles of body fat
distribution were calculated using nonparametric tests,
either the Kruskal Wallis or the Chi Square test when
appropriate.
A linear regression was used for the multivariate ana-
lysis. Factors with a p < 0.1 in the correlation analysis were
included in this multivariate analysis. All tests were two
sided. Associations or differences of p <0.05 were deemed
significant. All the data was analyzed using SPSS 20.0 for
Windows (IBM SPSS, IBM Corp., Armonk, NY).
Results
Clinical patient characteristics are listed in Table 1. Peri-
prostatic adipose tissue seems to be independent of
Table 1 Clinical, implant and dosimetric characteristics
Parameter Mean/median (SD)
BMI 28.1/28.0 (4.5)
Activity (mCi) 0.48/0.44 (range 0.32-0.68)
Prostate volume (cc) 36.2 (11.6)
Prostate V100 (%) 96.5/94.9 (5.7)
Prostate V150 (%) 62.8/63.5 (14.0)
Prostate D90 (Gy) <130 Gy 159.6/158.0 (26.3) 14.7%
Rectum R100 (cc) 0.80/0.62 (0.9)
Rectum R150 (cc) 0.19/0.08 (0.6)
Rectum D2 (Gy) 212/208 (96.8)
Age (y) 68.2/69 (6.4)
PSA (mg/mL) PSA <10 (mg/mL) 6.26/5.8 (3.3) 92%
Gleason 6/7 69.2%/30.8%
T1 (AJCC 1997) T2 69% 31%
D90: minimum dose received by 90% of prostate volume at Day 30.
V100: prostate volume receiving 100% of the prescribed dose at Day 30.
R100/R150: volume of anterior rectal wall receiving 100%/150% of the
prescribed dose in cc.
D2: isodose that encompassed 2% of the rectal volume in Gy.
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correlated with BMI (r = 0.245, p = 0.008) and only
weakly correlated with the other fat measurements (r =
0.31-0.37, p < 0.001), while BMI was correlated with all
other fat measurements (≥0.58, p < 0.001) and the other
fat measurements were strongly correlated with each
other (r = 0.5-0.87, p < 0.001) (Table 2).
All body fat measurements were weakly (range cor-
relation coeff. -0.19 to –0.29) but significantly (p = 0.02
to <0.001) inversely correlated with the dose to the rec-
tum, except for periprostatic fat. (p = 0.38-0.83 for the
D2, V100 and V150 of the rectum).
34% of patients had an R100 of >1.0 cc and 23% had an
R100 of >1.3 cc. Compared to patients with an R100
of <1.3 cc, patients with the clinically significant R100
of >1.3 cc had significantly less (p = 0.004) visceral fat
(mean 63 cc, SD 27 cc vs. 78 cc, SD 33), less subcutaneous
fat at the level of the iliac crest (117 cc SD41 vs. 138 cc
SD 52, p = 0.046) and a lower BMI (26.8 kg/m2 vs.
28.5 kg/m2, p = 0.02). Table 3 lists the R100 of the rec-
tum according to fat tertiles of the different adipose
tissues and BMI. When grouped according to theTable 2 Correlation between body mass index (BMI) and
adipose fat distribution
Factor Median (range) Correlation with BMI
R = P=
Subcutaneous fat (iliac crest) 115.6 (26.06-315.5) 0.69 <0.001
Subcutaneous fat (symphysis) 123.7 (43.7-322.5) 0.687 <0.001
Visceral fat 69.1 (16.4-184.3) 0.599 <0.001
Periprostatic fat 13.4 (1.26-34.08) 0.245 0.008different BMI categories, patients who were normal
weight (≤25 kg/m2) overweight (25-30 kg/m2), obese
(30-35 kg/m2) or morbidly obese (>35 kg/m2) were not
more like likely to have an R100 > 1.3 cc (p = 0.2 Chi
Square test). See Figure 2 for a stratification of rectum
dosimetry according to BMI and Figure 3 for stratifica-
tion according to tertile of visceral fat.
Results were very similar when comparing an R100
of <1.0 cc across the tertiles of visceral fat (p = 0.02),
subcutaneous fat at the level of the iliac crest (p = 0.01),
periprostatic fat (p = 0.7) and subcutaneous fat at the
symphysis level (p = 0.2).
Table 3 lists rectum dosimetry according to tertile of fat
tissue measurement. Dosimetry to the rectum decreases
significantly over all 3 tertiles for visceral fat, subcutaneous
fat (iliac crest level) and the 4 BMI categories but not for
periprostatic fat or subcutaneous fat (symphysis level).
Different linear regression models were then tested in
a multivariate analysis to predict the dose to the rectum
(R100, R150 and D2) as a continuous variable. Most
models had a very small Adjusted R square value (max
0.12). Therefore these models have very little predictive
(max 12%) value and we decided not to report them in
this paper.
It is important to mention that none of the fat tissue
measurements were correlated to prostate volume, age,
Gleason score or prostate specific antigen (PSA). BMI
was only weakly correlated to age (r = -0.16, p = 0.02).
Discussion
Rectal bleeding following prostate brachytherapy occurs
in less than 10% of patients [2,14]. Known risk factors
for rectal bleeding are the addition of EBRT [14], age
[15] and dose to the rectum. Tran et al. [4] reported a
much higher dose R100 for patients with rectal bleeding
compared to patients without rectal bleeding (2.3 cc vs.
0.76 cc). Keyes et al. [2] found that patients without any
rectal toxicity had a mean R100 of 0.96 cc while those
with grade 1-2 rectal toxicity had an R100 ≥ 1.3 cc.
Physicians practicing brachytherapy realize that the dose
to the rectum is very difficult to predict intraoperatively
even though care is taken to keep it as low as possible. To
our knowledge, this is the first report to measure adipose
tissue distribution and its influence on rectum dosimetry.
Our interest in this subject was awakened by our previous
research investigating the influence of BMI and adipose
tissue distribution on PSA-bounce [11,16] and the findings
of Patil et al. [9], which showed that a higher BMI was
associated with a lower dose to the rectum. This finding is
not surprising, as it seems intuitive that fatty tissue
between the rectum and the prostate acts as a radiation
buffer.
We can confirm that BMI in general and fat distribu-
tion have an influence on the dose to the rectum. We
Table 3 Rectum dosimetry according to tertiles of adipose tissue measurement
R100 P=* R150 P= D2 P=
Visceral fat 0.003 0.004 0.013
1st Tertile 1.2/0.98 (0.8) 0.17/0.36 (0.4) 272/257 (108)
2nd Tertile 1.1/1.1 (0.8) 0.33/0.23 (0.4) 255/244 (87)
3rd Tertile 0.7/0.5 (0.7) 0.16/0.07 (0.3) 213/204 (96)
Subcut. fat (iliac crest) 0.004 0.01 0.017
1st Tertile 1.2/0.98 (0.9) 0.33/0.17 (0.4) 274/257 (112)
2nd Tertile 1.0/1.0 (0.7) 0.3/0.2 (0.3) 251/241 (85)
3rd Tertile 0.7/0.5 (0.7) 0.17/0.07 (0.3) 216/205 (94)
Subcut. fat (symphysis) 0.09 0.14 0.23
1st Tertile 1.1/0.8 (0.9) 0.26/0.11 (0.4) 260/244 (119)
2nd Tertile 1.0/1.0 (0.7) 0.29/0.14 (0.3) 242/230 (87)
3rd Tertile 0.70/0.52 (0.6) 0.17/0.06 (0.2) 217/207 (94)
Periprostatic Fat 0.86 0.55 0.61
1st Tertile 0.96/0.72 (0.9) 0.25/0.16 (0.4) 238/204 (131)
2nd Tertile 0.93/0.89 (0.7) 0.24/0.16 (0.3) 238/239 (78)
3rd Tertile 0.86/0.73 (0.7) 0.24/0.08 (0.3) 243/226 (107)
BMI 0.001 0.003 <0.001
<25 kg/m2 (n = 43) 0.96/0.75 (0.8) 0.23/0.08 (0.3) 239/221 (110)
25-30 kg/m2 (n = 98) 0.98/0.73 (0.9) 0.28/0.12 (0.4) 239/227 (90)
30-35 kg/m2 (n = 53) 0.65/0.36 (0.7) 0.26/0.03 (0.8) 191/178 (92)
>35 kg/m2 (n = 17) 0.38/0.22 (0.5) 0.06/0.01 (0.1) 156/157 (75)
Results are in mean/median (SD). Differences between tertiles were calculated using the Kruskal Wallis nonparametric test. *Bold values indicate a significant result
R100/R150: volume of anterior rectal wall receiving 100%/150% of the prescribed dose in cc.
D2: isodose that encompassed 2% of the rectal volume in Gy.
Figure 2 Box plot of V100 of rectum dosimetry stratified by
BMI. R100: volume of anterior rectal wall receiving 100% of the
prescribed dose in cc. The middle line in the box is the median. The
length of box is the interquartile range (IQR). The “o” symbols
indicate values more than 1.5 IQR’s but less than 3 IQR’s.
Abbreviations: BMI; body mass index.
Figure 3 Box plot of V100 of rectum dosimetry stratified by
tertiles of visceral fat R100: volume of anterior rectal wall
receiving 100% of the prescribed dose in cc. The middle line in
the box is the median. The length of box is the interquartile range
(IQR). The “o” symbols indicate values more than 1.5 IQR’s but less
than 3 IQR’s. Abbreviations: BMI; body mass index.
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ceral and subcutaneous fat content at the iliac crest level
have lower doses to the rectum. As the linear regression
analysis found that the various fat measurements and
BMI were only weakly predictive of the dose to the rec-
tum, body fat remains only one of the many variables to
consider. Rectal filling, another important factor influencing
the rectal dose, was not measured in this study. As rectal
filling can change from day to day, it is an unreliable vari-
able affecting the dose to the rectum. One can argue that
measuring the distance between the rectum and prostate at
the time of seed implantation might be a better predictor of
the rectal dose. We chose not to use this measurement as
we feel this distance is dependent on how deep and at what
angle the trans-rectal ultrasound (TRUS) probe is inserted.
Another factor to consider is the timing of the dosi-
metric evaluation, as it was have previously described
that less prostatic edema leads to a higher dose [17].
We decided to directly measure adipose tissue in various
regions and specifically around the prostate to see whether
this would be a better predictor of dose to the rectum than
the BMI. We expected the periprostatic fat to be predictive
of dose to the rectum. Surprisingly, the periprostatic fat
was the least correlated of all the fat measurements to
the received rectal dose. A simple explanation may be that
the adipose tissue between the rectum and prostate is
compressed during the procedure. However, this compres-
sion is relieved by the time of the evaluation of the im-
plant, 30 days after the procedure. At this point, the dose
to the rectum should be lower for patients with a large fat
pad. Patil et al. [9] and our present study are so far the
first to report an influence of BMI on rectal dose in pros-
tate brachytherapy. Their RV100 was very similar to ours
with 0.79 cc but with a smaller standard deviation (0.49
versus 0.89). Interestingly, they reported a very similar
mean BMI (27.8 kg/m2 ± 4.2) compared to our cohort
(28.0 kg/m2 ± 4.5).
We also found that BMI was itself strongly correlated to
all adipose tissue measurements except for periprostatic
adipose tissue. Therefore, we believe that measurement of
adipose tissue distribution has no advantage over meas-
urement of the BMI to predict dose to the rectum.
We believe that investigation of the periprostatic adi-
pose tissue is an interesting and nascent field. While ex-
ploring ways to measure the periprostatic adipose tissue
and reviewing the literature, we realized the importance of
guidelines in this new research field. Current practices for
determining periprostatic adipose tissue vary greatly. One
center mentioned that it used in-house automatic soft-
ware, which included tissue in the levator ani sling [13].
We believe that including the tissue within the sling in-
duces a large bias as the volume depends largely on rec-
tum filling. Bhindi et al. [16] used the diameter of the
anterior fat pad as a surrogate, but there is also adiposetissue posterior and lateral to the prostate. Since part of
this volume depends on rectum filling, we decided to in-
clude the anterior fat pad as well as the fat lateral and pos-
terior to the prostate, but only outside of the levator ani
sling.
Ribeiro et al. have shown an influence of periprostatic
adipose tissue on prostate cancer aggressiveness in vitro
[18]. While all adipose tissue may produce soluble media-
tors, it may be the local mediators such as IL-6 regulated
pathways released by the periprostatic adipose tissue that
ultimately have an impact on prostate volume and pros-
tate cancer pathogenesis [19].
Conclusions
Specific adipose tissue measurements are not superior to
BMI in predicting dose to the rectum in permanent seed
brachytherapy. Periprostatic adipose tissue is not predic-
tive of dose to the rectum. We need to continue to iden-
tify potential factors that may predict the dose to the
rectum.
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